Efficacy of quetiapine in patients with bipolar I and II depression: A multicenter, prospective, open-label, observational study

Neuropsychiatric Disease and Treatment

Volumn 9, Issue , 2013, Pages 197-204

  Jeong, Jong Hyun ^a   Bahk, Won Myong ^a   Woo, Young Sup ^a   Seo, Ho Jun ^a   Hong, Seung Chul ^a   Jon, Duk In ^b   Min, Kyung Joon ^c   Yoon, Bo Hyun ^d  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b Hallym University College of Medicine   (South Korea)

^c Chung Ang University College of Medicine   (South Korea)

^d Naju National Hospital   (South Korea)

Author keywords

Bipolar depression; Observational study; Quetiapine; Therapeutic efficacy

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; HYPNOTIC SEDATIVE AGENT; MOOD STABILIZER; QUETIAPINE;

ADULT; ARTICLE; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; FATIGUE; FEMALE; HUMAN; HYPOMANIA; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPEN STUDY; PATIENT COMPLIANCE; REMISSION; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; WEIGHT CHANGE;

EID: 84873742563     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S41081     Document Type: Article

References (29)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision: DSM-IV-TR®. Washington, DC: American Psychiatric Association; 2000.
2. Shastry BS. Bipolar disorder: an update. Neurochem Int. 2005;46(4): 273-279.
3. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530-537.
4. Kupfer DJ, Frank E, Grochocinski VJ, Cluss PA, Houck PR, Stapf DA. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry. 2002;63(2):120-125.
5. Sachs GS, Printz DJ, Kahn DA, et al. The expert consensus guideline series: medication treatment of bipolar disorder 2000. Postgrad Med. 2000;Spec No:1-104.
6. Min KJ, Shin YC, Jon DI, Yoon BH, Kwon JS, Bahk WM. Korean medication algorithm for bipolar disorder (III): depressive episode. Korean J Psychopharmacol. 2003;14(4):336-346.
7. Post RM, Calabrese JR. Bipolar depression: the role of atypical antipsychotics. Expert Rev Neurother. 2004;4(6 Suppl 2):S27-S33.
8. Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 2005;7(Suppl 3):5-69.
9. Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord. 2006;8(6):721-739.
10. Min KJ, Bahk WM, Seo JS, et al. Korean medication algorithm for bipolar disorder 2006 (III): depressive episode. Korean J Psychopharmacol. 2006;17:436-448.
11. Sajatovic M, Mullen JA, Sweitzer DE. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry. 2002;63(12):1156-1163.
12. Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162(7):1351-1360.
13. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26(6):600-609.
14. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73(3):159-171.
15. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
16. Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry. 1997;170:205-228.
17. Vieta E, Gasto C, Colom F, et al. Role of risperidone in bipolar II: an open 6-month study. J Affect Disord. 2001;67(1-3):213-219.
18. Montgomery SA. Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders. Int Clin Psychopharmacol. 2002; 17(Suppl 4):S9-S15.
19. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079-1088.
20. Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol. 2006;20(4): 536-546.
21. Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010;71(2):150-162.
22. Judd LL, Akiskal HS, Schettler PJ, et al. The comparative clinical phenotype and long term longitudinal episode course of bipolar I and II: a clinical spectrum or distinct disorders? J Affect Disord. 2003; 73(1-2):19-32.
23. Mantere O, Suominen K, Valtonen HM, et al. Differences in outcome of DSM-IV bipolar I and II disorders. Bipolar Disord. 2008;10(3): 413-425.
24. Colom F, Vieta E. Non-adherence in psychiatric disorders: misbehaviour or clinical feature? Acta Psychiatr Scand. 2002;105(3):161-163.
25. Vieta E. Improving treatment adherence in bipolar disorder through psychoeducation. J Clin Psychiatry. 2005;66(Suppl 1):24-29.
26. Maarbjerg K, Aagaard J, Vestergaard P. Adherence to lithium prophylaxis: I. Clinical predictors and patient's reasons for nonadherence. Pharmacopsychiatry. 1988;21(3):121-125.
27. Colom F, Vieta E, Martinez-Aran A, Reinares M, Benabarre A, Gasto C. Clinical factors associated with treatment noncompliance in euthymic bipolar patients. J Clin Psychiatry. 2000;61(8):549-555.
28. Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry. 2005; 66(1):111-121.
29. McIntyre RS, Brecher M, Paulsson B, Huizar K, Mullen J. Quetiapine or haloperidol as monotherapy for bipolar mania - a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol. 2005;15(5):573-585.